GILD is no doubt interested in Leronlimab for both the HIV combo and mono therapy indications. There is no way they can avoid the value of both indications at this point. Yes, mono still has to complete a pivotal trial but does anyone doubt that it won’t pass with flying colors given past results?

NP insinuated that partnering/licensing is waiting on the FDA meetings in the next couple of month and submission of the BLA. I’m torn on whether to go alone or partner, but I think that decision hinges on cancer results. IMO, if cancer looks promising, CYDY will license HIV and go alone for cancer.